News
April 5th , 2011 – Biotools B&M Labs, S.A., 2B BlackBio & Kilpest India launch novel biotech JV plant in Bhopal, India
NOVEL BIOTECH INDO-SPANISH JV PROJECT INAUGURATED BY MINISTER OF HEALTH PARLIAMENTARY AFFAIRS GOVERNMENT OF MADHYA PRADESH, INDIA
April 5th, 2011. Bhopal, India - Dr.Narottam Mishra, Parliamentary Affairs Government of Madhya Pradesh along with Mr. Erik Rovina Mardones Commercial Counsellor Embassy of Spain & Mr.Adrian Gutierrez Chief Representative CDTI (Spain’s National Innovation Agency ministry of Science & Technology), - today inaugurated the novel biotech plant of Indo Spanish JV company 3B Blackbio Biotech India Ltd.
M/s Kilpest India Ltd - A leading 38 yrs old agrochemical company in Central India has entered into a joint venture with two Spanish biotechnology companies M/S Biotools B&M Labs S.A (A leading Spanish Biotechnology company founded in 1996, focused on research, development and manufacture of recombinant enzymes and other tools for molecular biology) and its spin-off company 2B Blackbio S.L., Madrid (Rapidly growing Biotech company focused on Personalised medicine, nutrigenomics & pharmacogenomics, developing products based on technologies of Micro sequencing , microarrays & other molecular techniques) to form the new joint venture company 3B Blackbio Biotech India Ltd.
The inauguration of the plant was also attended by our numerous prestigious customers, Vendors, Clinicians, representatives of the city of Bhopal along with Mr. Pedro Franco de Sarabia (President & CEO of Biotools B&M Labs.), Mr.R.K.Dubey (Chairman , M.D of M/s Kilpest India Ltd), as well as main executives of both companies.
The company has put up a most modern and state of art GMP compliant biotech plant in Industrial area, Govindpura, Bhopal. This is first novel plant of its kind in central India and it will manufacture Molecular Biology Reagents and Molecular Diagnostic Kits based on Spanish patented technology for various diseases. Further with target to lead the research and development of new tools in the field of personalized medicine, medical diagnostics, pharmacogenomics, as well as provide diagnostic tests to predict drug treatment effectiveness (Companion Diagnostics) and enter the field of nutrigenomics.
3B BlackBio Biotech India Ltd. will use and adapt a wide spectrum of technologies that include the most innovative microsequencing platforms, protein arrays and other molecular analysis solutions in the areas of metabolic disorders, pharmacogenetics, oncology, cardiovascular diseases, microbiology and wellness.
The new Joint Venture will introduce in India an innovative site-directed microsequencing platform that combines ease of use and cost competitiveness, allowing the introduction of companion diagnostics to one of the biggest global Healthcare markets. These tools are also becoming essential for Pharma companies in order to show the efficiency of newly developed drugs and penetrate in that way markets in an easier way, as well as differentiating themselves from other competitors. It is expected that in the next 5 years most Healthcare systems will request companion diagnostic tests especially in oncology and metabolic disorders before prescription and treatment can be initiated.
The Company will be focusing its Marketing plans during initial years in India and adjoining SAARC Countries.
www.3bblackbio.com
www.blackbio.eu
www.kilpest.com
|
